Houston

Running trials

• Recruiting

  TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy

  NCT07223203· Phase 3· Source

• Recruiting

  Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation

  NCT07211958· Phase 3· Source

• Recruiting

  Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer

  NCT07085767· Phase 3· Source

• Recruiting

  Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease

  NCT07181109· Phase 3· Source

• Recruiting

  TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

  NCT07052903· Phase 3· Source

• Active, not recruiting

  A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation

  NCT07023731· Phase 1/2· Source

• Recruiting

  A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma

  NCT06600321· Phase 1· Source

• Active, not recruiting

  A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy

  NCT06393712· Phase 2· Source

• Active, not recruiting

  OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer

  NCT06016738· Phase 3· Source

• Active, not recruiting

  Assessment of Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solution

  NCT05044819· Phase 4· Source

• Recruiting

  ConTTRibute: A Global Observational Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)

  NCT04561518· Source

• Recruiting

  Registry of Participants With Generalized Myasthenia Gravis Treated With Alexion C5 Inhibition Therapies (C5ITs)

  NCT04202341· Source

• Active, not recruiting

  HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

  NCT04153149· Phase 3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Amyloidosis3 recruiting
• Acute myeloid leukemia1 recruiting
• Childhood cancers1 recruiting
• High blood pressure1 recruiting
• Liver and biliary tract cancer1 recruiting
• Metastatic breast cancer1 recruiting
• Myasthenia gravis1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3)

  NCT06272487· Phase 2· Source

• Terminated

  A Phase 1/2 Study to Evaluate ALN-KHK in Overweight to Obese Healthy Volunteers and Obese Patients With T2DM

  NCT05761301· Phase 1/2· Source

• Terminated

  A Dose Finding Study to Treat Bone Tumor(s)

  NCT06008483· Phase 1· Source

• Completed

  Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2)

  NCT05103332· Phase 2· Source

• Completed

  A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension

  NCT04936035· Phase 2· Source

• Terminated

  Assessment of Adjunctive Cannabidiol Oral Solution (GWP42003-P) in Children With Tuberous Sclerosis Complex (TSC), Dravet Syndrome (DS), or Lennox-Gastaut Syndrome (LGS) Who Experience Inadequately-controlled Seizures

  NCT04485104· Phase 3· Source